Compare RYN & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYN | GKOS |
|---|---|---|
| Founded | 1926 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.0B |
| IPO Year | 1994 | 2015 |
| Metric | RYN | GKOS |
|---|---|---|
| Price | $19.56 | $101.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $26.00 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 3.2M | 577.7K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 12.51% | N/A |
| EPS Growth | ★ 26.78 | N/A |
| EPS | ★ 3.03 | N/A |
| Revenue | $484,485,000.00 | ★ $507,442,000.00 |
| Revenue This Year | $214.96 | $23.34 |
| Revenue Next Year | $10.35 | $27.46 |
| P/E Ratio | $6.57 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $19.56 | $73.16 |
| 52 Week High | $28.14 | $130.23 |
| Indicator | RYN | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 27.84 | 37.84 |
| Support Level | N/A | $94.92 |
| Resistance Level | $22.53 | $104.66 |
| Average True Range (ATR) | 0.52 | 4.02 |
| MACD | -0.12 | -0.71 |
| Stochastic Oscillator | 2.20 | 22.45 |
Rayonier Inc is a timberland real estate investment trust engaged in the ownership, management, and investment of timberlands. The company operates through Southern Timber, Pacific Northwest Timber, and Real Estate segments. The Southern Timber and Pacific Northwest Timber segments are involved in harvesting timber and related activities, as well as value-added services such as licensing properties for hunting, leasing land for mineral extraction and communication infrastructure, land-based solutions including carbon capture and solar energy, and log trading. The Real Estate segment is engaged in land sales across various categories, as well as residential and commercial leasing activities. It generates the majority of its revenue from the Southern Timber segment.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.